---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-076682"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:25:04.755498+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M

## Summary
- JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.
- Net loss for FY2022: $109.2M ($4.79/share) vs $110.8M ($4.96/share) in FY2021; cash ~$100M.
- UGN-102 Phase 3 ENVISION fully enrolled (~220 patients); topline data for ENVISION and ATLAS expected mid-2023; NDA submission targeted for 2024.
- FY2023 guidance: JELMYTO revenue $76-86M; operating expenses $135-145M; cash expected to fund operations into H1 2024.

## SEC filing metadata
- accession: 0001193125-23-076682
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/d680885d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-076682
- JSON: https://secwatch.observer/filing/0001193125-23-076682.json
- Plain text: https://secwatch.observer/filing/0001193125-23-076682.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the full year ended December 31, 2022 results: revenue $64.4 million.
  - Period: the full year ended December 31, 2022
  - Revenue: $64.4 million
  - Result: reported results
  source text: Net product revenues were $64.4 million for the full year 2022, compared to $48.0 million for the full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm
- Earnings Releases
  UroGen Pharma Ltd. reported the fourth quarter ended December 31, 2022 results: revenue $18.1 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $18.1 million
  - Result: reported results
  source text: UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.